These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 27673712)
1. How much of a problem is resistance in treating hepatitis C? Forton DM Curr Opin Infect Dis; 2016 Dec; 29(6):625-631. PubMed ID: 27673712 [TBL] [Abstract][Full Text] [Related]
3. Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life. Ren S; Wei F; Jin Y; Lu J; He Z; Ma L; Zheng Y; Wang J; Chen X Antivir Ther; 2020; 25(5):245-255. PubMed ID: 32936785 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies. Grandal M; Pernas B; Tabernilla A; Mariño A; Álvarez H; Valcarce N; Mena A; Castro-Iglesias A; Pérez AB; Delgado M; Poveda E J Med Virol; 2018 Jun; 90(6):1094-1098. PubMed ID: 29427437 [TBL] [Abstract][Full Text] [Related]
5. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Di Maio VC; Cento V; Lenci I; Aragri M; Rossi P; Barbaliscia S; Melis M; Verucchi G; Magni CF; Teti E; Bertoli A; Antonucci F; Bellocchi MC; Micheli V; Masetti C; Landonio S; Francioso S; Santopaolo F; Pellicelli AM; Calvaruso V; Gianserra L; Siciliano M; Romagnoli D; Cozzolongo R; Grieco A; Vecchiet J; Morisco F; Merli M; Brancaccio G; Di Biagio A; Loggi E; Mastroianni CM; Pace Palitti V; Tarquini P; Puoti M; Taliani G; Sarmati L; Picciotto A; Vullo V; Caporaso N; Paoloni M; Pasquazzi C; Rizzardini G; Parruti G; Craxì A; Babudieri S; Andreoni M; Angelico M; Perno CF; Ceccherini-Silberstein F; Liver Int; 2017 Apr; 37(4):514-528. PubMed ID: 28105744 [TBL] [Abstract][Full Text] [Related]
6. Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection. Lahser F; Galloway A; Hwang P; Palcza J; Brunhofer J; Wahl J; Robertson M; Barr E; Black T; Asante-Appiah E; Haber B Antivir Ther; 2018; 23(7):593-603. PubMed ID: 30038064 [TBL] [Abstract][Full Text] [Related]
7. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir. Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932 [TBL] [Abstract][Full Text] [Related]
8. Resistance to DAAs: When to Look and When It Matters. Wyles DL Curr HIV/AIDS Rep; 2017 Dec; 14(6):229-237. PubMed ID: 29116550 [TBL] [Abstract][Full Text] [Related]
9. Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed. Yoshida K; Hai H; Tamori A; Teranishi Y; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467359 [TBL] [Abstract][Full Text] [Related]
10. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population. Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115 [TBL] [Abstract][Full Text] [Related]
11. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. Harrington PR; Komatsu TE; Deming DJ; Donaldson EF; O'Rear JJ; Naeger LK Hepatology; 2018 Jun; 67(6):2430-2448. PubMed ID: 29194682 [TBL] [Abstract][Full Text] [Related]
12. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study. Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116 [TBL] [Abstract][Full Text] [Related]
13. Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience. Milazzo L; Magni C; Niero F; Schiavini M; Lai A; Cento V; Binda F; Antinori S; Sollima S Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1231-1234. PubMed ID: 28877086 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors. Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798 [TBL] [Abstract][Full Text] [Related]
15. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. Wyles D; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Martin R; Afdhal NH; Kowdley KV; Lawitz E; Brainard DM; Miller MD; Mo H; Gane EJ J Hepatol; 2017 Apr; 66(4):703-710. PubMed ID: 27923693 [TBL] [Abstract][Full Text] [Related]
16. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. Sayan M; Yıldırım FS; Akhan S; Yıldırım AA; Şirin G; Cabalak M; Demir M; Can S; Ersöz G; Altıntaş E; Ensaroğlu F; Akbulut A; Şener A; Deveci A Int J Infect Dis; 2020 Jun; 95():84-89. PubMed ID: 32302766 [TBL] [Abstract][Full Text] [Related]
17. Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes. Fourati S; Rodriguez C; Soulier A; Donati F; Hamadat S; Poiteau L; Demontant V; Brillet R; Ahnou N; Gricourt G; Chevaliez S; Ahmed-Belkacem A; Pawlotsky JM Aliment Pharmacol Ther; 2020 Nov; 52(10):1583-1591. PubMed ID: 32886807 [TBL] [Abstract][Full Text] [Related]
18. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures. Jeong Y; Jin B; Lee HW; Park HJ; Park JY; Kim DY; Han KH; Ahn SH; Kim S J Viral Hepat; 2018 Nov; 25(11):1251-1259. PubMed ID: 29768695 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Sorbo MC; Cento V; Di Maio VC; Howe AYM; Garcia F; Perno CF; Ceccherini-Silberstein F Drug Resist Updat; 2018 Mar; 37():17-39. PubMed ID: 29525636 [TBL] [Abstract][Full Text] [Related]
20. Virological patterns of HCV patients with failure to interferon-free regimens. Starace M; Minichini C; De Pascalis S; Macera M; Occhiello L; Messina V; Sangiovanni V; Adinolfi LE; Claar E; Precone D; Stornaiuolo G; Stanzione M; Ascione T; Caroprese M; Zampino R; Parrilli G; Gentile I; Brancaccio G; Iovinella V; Martini S; Masarone M; Fontanella L; Masiello A; Sagnelli E; Punzi R; Salomone Megna A; Santoro R; Gaeta GB; Coppola N J Med Virol; 2018 May; 90(5):942-950. PubMed ID: 29315640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]